Dhacort cream steroid

HPA-axis suppression was studied in 4 sequential cohorts of pediatric patients with atopic dermatitis covering at least 20% of the body surface area, treated once daily or twice daily with VANOS Cream. The first cohort of 31 patients (mean % BSA) 12 to < 18 years old; the second cohort included 31 patients (mean % BSA) 6 to < 12 years old; the third cohort included 30 patients (mean % BSA) 2 to < 6 years old; the fourth cohort included 31 patients (mean % BSA) 3 months to < 2 years old. VANOS Cream caused HPA-axis suppression in 1 patient in the twice daily group in Cohort 1, 2 patients in the twice daily group in Cohort 2, and 1 patient in the twice daily group in Cohort 3. Follow-up testing 14 days after treatment discontinuation, available for all 4 suppressed patients, demonstrated a normally responsive HPA-axis. Signs of skin atrophy were present at baseline and severity was not determined making it difficult to assess local skin safety. Therefore, the safety of VANOS Cream in patients younger than 12 years of age has not been demonstrated.

Dhacort cream steroid

dhacort cream steroid

Media:

dhacort cream steroid